JP2011525191A - 免疫応答を誘発するための組成物、方法およびキット - Google Patents

免疫応答を誘発するための組成物、方法およびキット Download PDF

Info

Publication number
JP2011525191A
JP2011525191A JP2011514851A JP2011514851A JP2011525191A JP 2011525191 A JP2011525191 A JP 2011525191A JP 2011514851 A JP2011514851 A JP 2011514851A JP 2011514851 A JP2011514851 A JP 2011514851A JP 2011525191 A JP2011525191 A JP 2011525191A
Authority
JP
Japan
Prior art keywords
antigen
cmv
cell
cells
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011514851A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011525191A5 (https=
Inventor
サンプソン，ジヨン・エイチ
ミツチエル，デユアン・エイ
Original Assignee
デユーク・ユニバーシテイ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by デユーク・ユニバーシテイ filed Critical デユーク・ユニバーシテイ
Publication of JP2011525191A publication Critical patent/JP2011525191A/ja
Publication of JP2011525191A5 publication Critical patent/JP2011525191A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55533—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55538—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/812—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/47—Brain; Nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
JP2011514851A 2008-06-20 2009-06-19 免疫応答を誘発するための組成物、方法およびキット Pending JP2011525191A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7458208P 2008-06-20 2008-06-20
US61/074,582 2008-06-20
PCT/US2009/047987 WO2009155535A2 (en) 2008-06-20 2009-06-19 Compositions, methods and kits for eliciting an immune response

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015016782A Division JP2015134767A (ja) 2008-06-20 2015-01-30 免疫応答を誘発するための組成物、方法およびキット

Publications (2)

Publication Number Publication Date
JP2011525191A true JP2011525191A (ja) 2011-09-15
JP2011525191A5 JP2011525191A5 (https=) 2012-08-09

Family

ID=41434717

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2011514851A Pending JP2011525191A (ja) 2008-06-20 2009-06-19 免疫応答を誘発するための組成物、方法およびキット
JP2015016782A Pending JP2015134767A (ja) 2008-06-20 2015-01-30 免疫応答を誘発するための組成物、方法およびキット
JP2016249706A Active JP6342982B2 (ja) 2008-06-20 2016-12-22 免疫応答を誘発するための組成物、方法およびキット

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2015016782A Pending JP2015134767A (ja) 2008-06-20 2015-01-30 免疫応答を誘発するための組成物、方法およびキット
JP2016249706A Active JP6342982B2 (ja) 2008-06-20 2016-12-22 免疫応答を誘発するための組成物、方法およびキット

Country Status (8)

Country Link
US (12) US8425898B2 (https=)
EP (4) EP3156069B8 (https=)
JP (3) JP2011525191A (https=)
CN (1) CN102123732A (https=)
AU (1) AU2009259923B2 (https=)
CA (1) CA2728739C (https=)
DK (1) DK3156069T3 (https=)
WO (1) WO2009155535A2 (https=)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013523824A (ja) * 2010-04-06 2013-06-17 ジョン ダブリュ． ホラデイ、 癌を治療する方法
JP2015536937A (ja) * 2012-10-30 2015-12-24 レッドヴァックス・ゲーエムベーハー ヒトサイトメガロウイルス感染に対する組換え粒子ベースのワクチン
JP2019535665A (ja) * 2016-10-21 2019-12-12 モデルナティーエックス， インコーポレイテッド ヒトサイトメガロウイルスワクチン
WO2021206104A1 (ja) * 2020-04-08 2021-10-14 アステラス製薬株式会社 がんの処置に用いるｐｐ６５含有人工アジュバントベクター細胞
JP2022547298A (ja) * 2019-09-09 2022-11-11 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫療法組成物
JP2024506550A (ja) * 2021-01-29 2024-02-14 ティーヘルパー・アーエス 治療剤及び診断剤並びにその使用

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008116468A2 (en) 2007-03-26 2008-10-02 Dako Denmark A/S Mhc peptide complexes and uses thereof in infectious diseases
EP3620465B1 (en) 2007-07-03 2025-02-19 Dako Denmark A/S Improved methods for generation, labeling and use of mhc multimers
US10611818B2 (en) 2007-09-27 2020-04-07 Agilent Technologies, Inc. MHC multimers in tuberculosis diagnostics, vaccine and therapeutics
DK2254592T3 (da) 2008-02-28 2019-09-09 Dako Denmark As MHC-multimerer til Borrelia-diagnostik og sygdom
EP3156069B8 (en) * 2008-06-20 2020-10-21 Duke University Compositions, methods, and kits for eliciting an immune response
WO2010009735A2 (en) 2008-07-23 2010-01-28 Dako Denmark A/S Combinatorial analysis and repair
GB0817244D0 (en) 2008-09-20 2008-10-29 Univ Cardiff Use of a protein kinase inhibitor to detect immune cells, such as T cells
US11992518B2 (en) 2008-10-02 2024-05-28 Agilent Technologies, Inc. Molecular vaccines for infectious disease
WO2010037402A1 (en) 2008-10-02 2010-04-08 Dako Denmark A/S Molecular vaccines for infectious disease
EP2697248B1 (en) * 2011-04-15 2020-03-11 Nauclér, Cecilia Genetic variant of cytomegalovirus (cmv)
CN102363818B (zh) * 2011-06-28 2013-01-02 同昕生物技术（北京）有限公司 同时检测人ebv、bkv和 cmv的三重实时荧光定量pcr方法及试剂盒
WO2014127148A1 (en) * 2013-02-14 2014-08-21 The J. David Gladstone Institutes Compositions and methods of use thereof for identifying anti-viral agents
EP3049092A4 (en) * 2013-09-24 2017-09-06 Duke University Compositions, methods and kits for eliciting an immune response
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
US9974848B2 (en) 2013-11-14 2018-05-22 Duke University Tetanus toxoid and CCL3 improve DC vaccines
EP3074770B1 (en) * 2013-11-26 2020-04-29 Duke University Immune monitoring to predict and prevent infection
AU2015343239B2 (en) 2014-11-05 2021-06-03 Memorial Sloan Kettering Cancer Center Methods of selecting T cell line and donor thereof for adoptive cellular therapy
US20180133327A1 (en) 2015-03-16 2018-05-17 Amal Therapeutics Sa Cell Penetrating Peptides and Complexes Comprising the Same
WO2016154620A1 (en) * 2015-03-26 2016-09-29 University Of Houston System Integrated functional and molecular profiling of cells
WO2016209816A1 (en) 2015-06-26 2016-12-29 Memorial Sloan Kettering Cancer Center Methods of treating cmv retinitis by t cell therapy
AU2016342045A1 (en) 2015-10-22 2018-06-07 Modernatx, Inc. Human cytomegalovirus vaccine
AU2016341309A1 (en) 2015-10-22 2018-06-07 Modernatx, Inc. Cancer vaccines
US11464839B2 (en) 2015-12-04 2022-10-11 Mayo Foundation For Medical Education And Research Methods and vaccines for inducing immune responses to multiple different MHC molecules
SG11201805186VA (en) 2016-01-20 2018-07-30 Fate Therapeutics Inc Compositions and methods for immune cell modulation in adoptive immunotherapies
JP7653759B2 (ja) 2016-01-20 2025-03-31 フェイト セラピューティクス，インコーポレイテッド 養子免疫療法における免疫細胞調節のための組成物および方法
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
PL3429618T3 (pl) 2016-03-16 2024-07-01 Amal Therapeutics Sa Kombinacja modulatora immunologicznego punktu kontrolnego i kompleks zawierający peptyd penetrujący komórkę, cargo i agonistę peptydu tlr do zastosowania w medycynie
HUE067838T2 (hu) 2016-09-21 2024-11-28 Amal Therapeutics Sa Egy sejtpenetráló peptidet, egy multiepitópot és egy TLR peptidagonistát tartalmazó fúzió rák kezelésére
AU2017330379B2 (en) 2016-09-23 2023-07-13 Memorial Sloan Kettering Cancer Center Generation and use in adoptive immunotherapy of stem cell-like memory T cells
EP3548049A4 (en) * 2016-12-05 2020-07-22 Fate Therapeutics, Inc. COMPOSITIONS AND METHODS FOR MODULATION OF IMMUNE CELLS IN ADOPTIVE IMMUNOTHERAPIES
US12338458B2 (en) 2017-05-25 2025-06-24 Memorial Sloan Kettering Cancer Center Use of the IL-15/IL-15Rα complex in the generation of antigen-specific T cells for adoptive immunotherapy
US11925663B2 (en) 2017-10-23 2024-03-12 Atara Biotherapeutics, Inc. Methods of managing tumor flare in adoptive immunotherapy
KR20250044945A (ko) * 2017-11-06 2025-04-01 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 기존의 미생물 면역을 활용한 암 치료
JP2021512950A (ja) 2018-02-02 2021-05-20 エスエル・ベクシジェン・インコーポレイテッドＳｌ Ｖａｘｉｇｅｎ， Ｉｎｃ． 新規なワクチンの免疫補助剤
WO2020127222A2 (en) 2018-12-17 2020-06-25 Immudex Aps Panel comprising borrelia mhc multimers
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
BR112021024157A2 (pt) * 2019-05-31 2022-04-26 Variation Biotechnologies Inc Composições imunoterapêuticas para tratamento de glioblastoma multiforme
JP7352040B2 (ja) * 2020-05-22 2023-09-27 フィロジェン エッセ．ピー．アー． 脳腫瘍の治療のためのＴＮＦα免疫コンジュゲート療法
TWI810589B (zh) 2020-06-21 2023-08-01 美商輝瑞股份有限公司 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽
EP4192494A4 (en) * 2020-08-06 2024-11-13 La Jolla Institute for Immunology Methods for treating and preventing cytomegalovirus infection
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
WO2022192323A1 (en) * 2021-03-09 2022-09-15 Board Of Regents, The University Of Texas System Low intensity ultrasound combination cancer therapies
CN117257925B (zh) * 2023-09-20 2024-05-28 青岛大学 基于人巨细胞病毒编码即刻早期蛋白ie的疫苗、其制备方法和应用
CN117169518B (zh) * 2023-11-03 2024-01-19 赛德特(北京)生物工程有限公司 T淋巴细胞制剂中的cd3抗体残留物的检测方法和试剂盒

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001519181A (ja) * 1997-10-14 2001-10-23 シティ・オブ・ホープ ヒトサイトメガロウィルスの免疫反応性ペプチドｃｔｌエピトープ
JP2003528887A (ja) * 2000-03-27 2003-09-30 シティ・オブ・ホープ ヒトサイトメガロウイルスの免疫ー反応性ペプチドｃｔｌエピトープ

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5833975A (en) 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US4957735A (en) 1984-06-12 1990-09-18 The University Of Tennessee Research Corporation Target-sensitive immunoliposomes- preparation and characterization
US6207161B1 (en) 1986-07-16 2001-03-27 City Of Hope Induction of cytolytic T-lymphocytes with cytomegalovirus polypeptides
US4906564A (en) 1987-03-13 1990-03-06 The United States Of America As Represented By The Secretary Of The Army Antigenic determinants recognized by antibodies obtained using a pathogenic agent or a derivative thereof that presents a restricted set of antigens
DE69132311T2 (de) 1990-09-25 2000-12-14 Cantab Pharmaceuticals Research Ltd., Cambridge Bei einer transkomplementenden zellinie erzeugter defektiver virenimpfstoff
JPH08506325A (ja) * 1993-01-28 1996-07-09 サンド ファーマスーティカル コーポレーション サイトメガロウイルスに対するヒトモノクローナル抗体
JPH08507784A (ja) 1993-03-19 1996-08-20 キャンタブ ファーマシューティカルズ リサーチ リミティド ウイルス・ワクチン
EP0914441A2 (en) * 1996-04-23 1999-05-12 The Wistar Institute Of Anatomy And Biology Novel human cytomegalovirus dna constructs and uses therefor
US5853719A (en) 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
US6074645A (en) * 1996-11-12 2000-06-13 City Of Hope Immuno-reactive peptide CTL epitopes of human cytomegalovirus
US6503503B1 (en) 1997-05-13 2003-01-07 Duke University Allogeneic cellular vaccine
US6013258A (en) 1997-10-09 2000-01-11 Zycos Inc. Immunogenic peptides from the HPV E7 protein
US6291446B1 (en) 1998-03-05 2001-09-18 Eli Lilly And Company Therapeutic treatment for cytomegalovirus infection
IL125608A0 (en) 1998-07-30 1999-03-12 Yeda Res & Dev Tumor associated antigen peptides and use of same as anti-tumor vaccines
WO2000011950A1 (en) 1998-08-31 2000-03-09 Oregon Health Science University Prevention of cell migration initiation with cmv us28 receptor antagonists
US6572856B1 (en) 1998-09-10 2003-06-03 The University Of Virginia Patent Foundation Methods for the prevention and treatment of cancer using anti-C3b(i) antibodies
US6350451B1 (en) 1999-06-25 2002-02-26 The Board Of Trustees Of The University Of Arkansas Immunotherapy of epithelial tumors using intralesional injection of antigens that induce a delayed type hypersensitivity reaction
US7005131B1 (en) 1999-08-13 2006-02-28 The Rockefeller University Protective antigen of Epstein Barr Virus
WO2001066138A2 (en) 2000-03-07 2001-09-13 U.S. Army Medical Research Institute Of Infectious Diseases Dna vaccines against poxviruses
EP1265916B1 (en) 2000-03-21 2005-12-21 Genzyme Corporation Therapeutic anti-cytomegalovirus compounds
EP1146119A1 (en) 2000-04-12 2001-10-17 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method for obtaining specific T-lymphocytes, and for identifying unknown epitopes
WO2002018954A2 (en) * 2000-08-30 2002-03-07 Chemocentryx, Inc. Inhibition of cmv infection and dissemination
US20040241140A1 (en) 2000-11-01 2004-12-02 Pavlakis George N. Expression vectors able to elicit improved immune response and methods of using same
CA2437201C (en) 2001-02-02 2008-11-18 Chemocentryx, Inc. Methods and compositions useful for stimulating an immune response
AUPR395801A0 (en) 2001-03-26 2001-04-26 Austin Research Institute, The Antibodies against cancer
AUPR593101A0 (en) * 2001-06-26 2001-07-19 Council Of The Queensland Institute Of Medical Research, The Cytomegalovirus t cell epitopes
AU2003268355A1 (en) 2002-09-03 2004-03-29 The Uab Research Foundation Localization of human cytomegalovirus nucleic acids and proteins in human cancer cells
US7740871B2 (en) 2002-09-19 2010-06-22 Johns Hopkins University School Of Medicine Cancer immunotherapy with a viral antigen-defined, immunomodulator-secreting cell vaccine
ATE353954T1 (de) 2002-10-11 2007-03-15 Sentoclone Therapeutics Ab Immuntherapie für krebs
AU2003296439B2 (en) 2002-12-10 2009-05-07 Argos Therapeutics, Inc. In situ maturation of dendritic cells
DK2311848T3 (da) 2002-12-23 2013-10-14 Vical Inc Kodon-optimerede polynukleotidbaserede vacciner mod human cytomegalovirus-infektion
US7163685B2 (en) 2003-04-16 2007-01-16 City Of Hope Human cytomegalovirus antigens expressed in MVA and methods of use
US20050232933A1 (en) 2003-09-30 2005-10-20 Zaia John A CMV-IE1 peptides and method of use
US7976845B2 (en) * 2004-11-29 2011-07-12 The Council Of The Queensland Institute Of Medical Research Human cytomegalovirus immunotherapy
US20100111992A1 (en) * 2006-05-01 2010-05-06 The Regents Of The University Of California Cytomegalovirus peptides and methods of use thereof
CA2700436C (en) 2006-09-28 2017-04-18 John S. Yu Cancer vaccines and vaccination methods
WO2009021150A2 (en) * 2007-08-08 2009-02-12 California Pacific Medical Center Platelet derived growth factor receptor supports cytomegalovirus infectivity
EP3156069B8 (en) * 2008-06-20 2020-10-21 Duke University Compositions, methods, and kits for eliciting an immune response
WO2010002983A2 (en) 2008-07-03 2010-01-07 Duke University Composition and methods for eliciting an immune response
US9974848B2 (en) * 2013-11-14 2018-05-22 Duke University Tetanus toxoid and CCL3 improve DC vaccines

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001519181A (ja) * 1997-10-14 2001-10-23 シティ・オブ・ホープ ヒトサイトメガロウィルスの免疫反応性ペプチドｃｔｌエピトープ
JP2003528887A (ja) * 2000-03-27 2003-09-30 シティ・オブ・ホープ ヒトサイトメガロウイルスの免疫ー反応性ペプチドｃｔｌエピトープ

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
JPN7013004237; Ｃｌｉｎ　Ｅｘｐ　Ｉｍｍｕｎｏｌ，　２００５，　１３９（３），　ｐ．４５８-６７ *
JPN7013004238; Ｂｒ　Ｊ　Ｈａｅｍａｔｏｌ，　２００３，　１２１（３），　ｐ．４２８-３８ *
JPN7013004239; Ｃａｎｃｅｒ　Ｒｅｓ，　２００２，　６２（１２），　ｐ．３３４７-５０ *
JPN7013004240; Ｃａｎｃｅｒ　Ｒｅｓ，　２００８　Ｆｅｂ，　６８（３），　ｐ．７２４-３０ *
JPN7013004241; Ｖａｃｃｉｎｅ，　２００７，　２５（６），　ｐ．１１３２-４１ *
JPN7013004242; Ｍｅｔｈｏｄｓ，　１９９９，　１９（１），　ｐ．１１４-２０ *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013523824A (ja) * 2010-04-06 2013-06-17 ジョン ダブリュ． ホラデイ、 癌を治療する方法
US9107878B2 (en) 2010-04-06 2015-08-18 Exocyte Therapeutics Pte, Ltd Methods of treating cancer
JP2017002054A (ja) * 2010-04-06 2017-01-05 エクソサイト セラピューティクス ピーティイー リミテッド 癌を治療する方法
JP2015536937A (ja) * 2012-10-30 2015-12-24 レッドヴァックス・ゲーエムベーハー ヒトサイトメガロウイルス感染に対する組換え粒子ベースのワクチン
JP2019535665A (ja) * 2016-10-21 2019-12-12 モデルナティーエックス， インコーポレイテッド ヒトサイトメガロウイルスワクチン
JP2022024088A (ja) * 2016-10-21 2022-02-08 モデルナティエックス インコーポレイテッド ヒトサイトメガロウイルスワクチン
JP2023106473A (ja) * 2016-10-21 2023-08-01 モデルナティエックス インコーポレイテッド ヒトサイトメガロウイルスワクチン
JP2025037989A (ja) * 2016-10-21 2025-03-18 モデルナティエックス インコーポレイテッド ヒトサイトメガロウイルスワクチン
JP2022547298A (ja) * 2019-09-09 2022-11-11 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫療法組成物
WO2021206104A1 (ja) * 2020-04-08 2021-10-14 アステラス製薬株式会社 がんの処置に用いるｐｐ６５含有人工アジュバントベクター細胞
JP2024506550A (ja) * 2021-01-29 2024-02-14 ティーヘルパー・アーエス 治療剤及び診断剤並びにその使用

Also Published As

Publication number Publication date
JP2017081960A (ja) 2017-05-18
US20130189224A1 (en) 2013-07-25
EP3156069B8 (en) 2020-10-21
US11351248B2 (en) 2022-06-07
US20220378906A1 (en) 2022-12-01
US20200246452A1 (en) 2020-08-06
EP2303319A2 (en) 2011-04-06
EP4218806A1 (en) 2023-08-02
WO2009155535A2 (en) 2009-12-23
CA2728739A1 (en) 2009-12-23
EP3766517A1 (en) 2021-01-20
US20210000944A1 (en) 2021-01-07
US11389530B2 (en) 2022-07-19
US8425898B2 (en) 2013-04-23
US9764026B2 (en) 2017-09-19
US20220370602A1 (en) 2022-11-24
US11376322B2 (en) 2022-07-05
EP2303319B1 (en) 2016-10-05
US9011835B2 (en) 2015-04-21
US20220387582A1 (en) 2022-12-08
CA2728739C (en) 2017-07-11
US11364295B2 (en) 2022-06-21
US20120288473A1 (en) 2012-11-15
US12070496B2 (en) 2024-08-27
US20210000943A1 (en) 2021-01-07
CN102123732A (zh) 2011-07-13
JP6342982B2 (ja) 2018-06-13
DK3156069T3 (da) 2020-09-21
US20200345837A1 (en) 2020-11-05
JP2015134767A (ja) 2015-07-27
US20220401552A1 (en) 2022-12-22
WO2009155535A3 (en) 2010-04-22
AU2009259923B2 (en) 2015-09-03
US10632190B2 (en) 2020-04-28
US20180153982A1 (en) 2018-06-07
US20150335732A1 (en) 2015-11-26
EP3156069B1 (en) 2020-08-05
AU2009259923A1 (en) 2009-12-23
EP3156069A1 (en) 2017-04-19
EP3766517B1 (en) 2022-11-02
EP2303319A4 (en) 2012-09-26

Similar Documents

Publication Publication Date Title
US12070496B2 (en) Compositions, methods and kits for eliciting an immune response
US9950056B2 (en) Compositions, methods and kits for eliciting an immune response
JP2021138721A (ja) Ｈｉｖ予備免疫化および免疫療法
US20110236345A1 (en) Composition and methods for eliciting an immune response
HK40059969A (en) Compositions, methods and kits for eliciting an immune response
US20210389301A1 (en) Compositions and methods for using cross-dressing to enhance anti-tumor immune responses

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120619

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120619

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131126

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140226

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140305

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140324

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140331

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140425

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140522

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20141001